
    
      Patient examinations:

      Baseline data will be gathered on demographic and clinical characteristics, medical history,
      treatments and medications. Before initiating intervention, individuals will be assessed for
      anemia and 25 (OH) D2 and electrolytes status. Any insufficiency or imbalance will be
      corrected by drug therapy or supplementation. At baseline and at all visits, half or one
      month intervals, routine laboratory tests for heart failure patients (including Complete
      blood count (CBC), electrolytes status, glucose, albumin, cholesterol, triglyceride, blood
      urea nitrogen (BUN), C-reactive Protein (CRP),creatinine, uric acid, ferritin, 25 (OH) D,
      B-type natriuretic peptide (BNP), thyroid function, Prealbumin, urine analysis), appetite
      status and anthropometric measurements (weight, Hip and waist circumference) will be
      performed. At baseline and by the end of month 6, body composition, muscle mass, hand grip
      strength, Short Physical Performance Battery (SPPB), plasma lactate and interleukin 6 (IL-6),
      GFR, depression status and quality of life will be assessed. Follow up duration will be one
      year for measuring readmission and mortality rate. If a study participant did not attend a
      visit, a staff of randomized clinical trial (RCT) center will attempt to reach her/him,
      her/his designated friend or family member by phone call.
    
  